Keyphrases
COVID-19
100%
Hospitalized Patients
46%
Remdesivir
35%
Patients with COVID-19
25%
SARS-CoV-2 Infection
19%
Confidence Interval
19%
Nucleocapsid Antigen
19%
Comorbidity
18%
National Cohort Study
18%
Placebo
18%
Vaccination
16%
C-reactive Protein
15%
Risk Factors
15%
Neutralizing Monoclonal Antibody
13%
Hospital Admission
12%
Immunological Biomarkers
12%
Vaccine-induced Immunity
12%
Improved Survival
12%
Vaccine Response
12%
T Cell Immunity
12%
Sustained Recovery
10%
Vaccine Dose
10%
SARS-CoV-2 Spike
9%
D-dimer
9%
Denmark
9%
Hospital Discharge
8%
Interleukin-6
8%
Odds Ratio
8%
Spike IgG
8%
Low-middle Income Countries
8%
SpO2
8%
Charlson Comorbidity Index
7%
Standard of Care
7%
Viral Factors
7%
Male Sex
7%
Patients with COVID-19 Infection
7%
Antibody Level
7%
Thrombocytopenia
7%
Malaria
7%
Mortality Risk
7%
Clinical Outcomes
7%
Placebo-controlled
6%
Continuous Monitoring
6%
Pulmonary Embolism
6%
Viral
6%
Readmission
6%
Hybrid Immunity
6%
Ensovibep
6%
Clinical Infectious Diseases
6%
30-day Mortality
6%
Medicine and Dentistry
COVID-19
63%
Severe Acute Respiratory Syndrome Coronavirus 2
40%
Infection
36%
Disease
17%
Remdesivir
16%
Placebo
14%
Virus Nucleocapsid
13%
Cohort Analysis
13%
C Reactive Protein
12%
Dexamethasone
12%
Cellular Immunity
12%
Biological Marker
9%
Thrombocytopenia
7%
COVID-19 Vaccine
7%
Low and Middle Income Countries
7%
Charlson Comorbidity Index
7%
Treatment Effect
6%
Hypoxia
6%
Randomized Controlled Trial
6%
4 Iodo 2,5 Dimethoxyamphetamine
6%
Procalcitonin
6%
Receptor Blocking
6%
Prospective Cohort Study
6%
Hyperimmune Globulin
6%
Host Factor
6%
Six Minute Walk Test
6%
Immunoglobulin
6%
Systematic Review
6%
Thrombosis
6%
Odds Ratio
5%
